Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-10-10
2006-10-10
Ulm, John D. (Department: 1649)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S069100, C435S252300, C435S320100, C530S330000
Reexamination Certificate
active
07119182
ABSTRACT:
The DNA encoding the cell surface receptor for thrombin has been cloned and sequenced. The availability of this DNA permits the recombinant production of thrombin receptor which can be produced at cell surfaces and is useful in assay systems both for the detection of thrombin and for the evaluation of candidate thrombin agonists and antagonists. Further, the elucidation of the structure of the thrombin receptor permits the design of agonist and antagonist compounds which are useful diagnostically and therapeutically. The availability of the thrombin receptor also permits production of antibodies specifically immunoreactive with the receptor per se or with specific regions thereof which are also useful diagnostically or therapeutically.
REFERENCES:
patent: 4187075 (1980-02-01), Nöller
patent: 4238195 (1980-12-01), Boguslaski et al.
patent: 4431739 (1984-02-01), Riggs
patent: 4783330 (1988-11-01), Furie
patent: 4859609 (1989-08-01), Dull et al.
patent: 4861865 (1989-08-01), Hortin
patent: 5132408 (1992-07-01), Baird et al.
patent: 5246832 (1993-09-01), Michelson et al.
patent: 5256766 (1993-10-01), Coughlin
patent: 5455228 (1995-10-01), Coller et al.
patent: 5688768 (1997-11-01), Coughlin et al.
patent: 5759994 (1998-06-01), Coughlin et al.
patent: 5798248 (1998-08-01), Coughlin et al.
patent: 5849507 (1998-12-01), Coughlin
patent: 5856448 (1999-01-01), Coughlin
patent: 5892014 (1999-04-01), Coughlin et al.
patent: 6024936 (2000-02-01), Coughlin et al.
patent: 6124101 (2000-09-01), Coughlin
patent: 6197541 (2001-03-01), Coughlin
patent: 0 205 270 (1986-12-01), None
patent: 0 214 709 (1987-03-01), None
patent: 0 238 473 (1987-09-01), None
patent: 0 272 703 (1988-06-01), None
patent: 0 278 148 (1988-08-01), None
patent: WO 88/03151 (1988-05-01), None
Suzuki (1988) Acta Haematol. JPN. 51:1655-1664.
Ngo et al. The Protein Folding Problem and Tertidry Structure Prediction Merz et al. (eds) Birkhauser Boston pp. 433 and 492-499.
Baniyash et al.,J. Biol. Chem., vol. 264, pp. 13252-13257 (1989).
Bar-Shavit et al.,Journal of Cell Biology, vol. 112(2), pp. 335-344 (1991).
Berndt et al.,Elsevier/North Holland Biomedical Press, pp. 43-74, “Platelets in Biology and Pathology” (1981).
Bode et al.,EMBO Journal, vol. 8, pp. 3467-3475 (1989).
Foster et al.,id., vol. 82, pp. 4673-4677 (1985).
Frost et al.,J. Cell. Biol., vol. 105, pp. 2551-2558 (1987).
Gearing et al.,EMBO Journal, vol. 8, pp. 3667-3676 (1989).
Greco et al.,Blood, vol. 75, pp. 1983-1990 (1990).
Gronke et al.,J. Biol. Chem., vol. 262, pp. 3030-3036 (1987).
Jackman et al.,Proc. Natl. Acad. Sci., vol. 84, pp. 6425-6429 (1987).
Martin et al.,Biochem., vol. 14, pp. 1308-1314 (1975).
Masu et al.,Nature, vol. 329, pp. 836-838 (1987).
Okamura et al.,J. Biol. Chem., vol. 253, pp. 3455- (1978).
Phillips,Thrombin Diath. Haemorrh., vol. 32, pp. 207-215 (1974).
Pipili-Synetos et al.,Biochem. Biophys. Res. Comm., vol. 171, pp. 913-919 (1990).
Tollefsen et al.,J. Biol. Chem., vol. 249, pp. 2646-2651 (1974).
Rasmussen et al.,FEBS Letters, vol. 288, pp. 123-128 (1991).
Ruda et al.,Biochemical Pharmacology, vol. 39(2), pp. 373-381 (1990).
Ruda et al.,Annals. New York Academy of Sciences, vol. 485, pp. 439-442 (1986).
Ruda et al.,Biochemical Pharmacology, vol. 37(12), pp. 2417-2426 (1988).
Sambrook et al.,op. cit., pp. 11.2-11.8.
Sambrook et al.,Molecular Cloning, 2nd edition, Cold Spring Harbor (NY) Press, Ch. 12.
Seed et al.,id., vol. 84, pp. 3365-3369 (1987).
Van Obberghen-Shilling et al.,FEBS Letters, vol. 262, pp. 330-334 (1990).
Vu et al.,Nature, vol. 353, pp. 674-677 (1991).
Vu et al.,Cell, vol. 64, pp. 1057-1058 (1991).
Walz et al.,Annals. New York Academy of Sciences, vol. 485, pp. 323-334 (1986).
Watson et al.,Recombinant DNA, 2nd ed., New York, Scientific American, p. 108.
Workman et al.,J. Biol. Chem., vol. 252, pp. 7118-7123 (1977).
Young et al.,Proc. Natl. Acad. Sci. USA, vol. 80, pp. 1194-1198 (1983).
D. Cosman,DNA and Protein Engineering Techniques, vol. 2, No. 1, pp. 1-3 (1990).
Edgington,Biotechnology, vol. 10, pp. 383-389 (1992).
Hui et al.,BBRC, vol. 184, pp. 790-796 (1992).
Scarborough et al.,J. Biol. Chem., vol. 267, pp. 13146-13149 (1992).
Sevier,Clin. Chem., vol. 27, pp. 1797-1806 (1981).
Yamamoto et al.,Thrombosis and Haemostasis, vol. 55(2), pp. 162-167 (1986).
Arrufo, A. and B. Seed. (1987). “Molecular Cloning of a CD28 cDNA by a High-Efficiency COS Cell Expression System,”Proc. Natl. Acad. Sci. USA84:8573-8577.
Berliner, S. et al. (1988). Generation and Characterization of Peptide-Specific Antibodies that Inhibit von Willebrand Factor Binding of Glycoprotein IIb-IIa Without Interacting With Other Adhesive Molecules. Selectivity is Conferred by Pro1743 and Other Amino Acid Residues Adjacent to the Sequence Arg1744-Gly1745-Asp1746,J Biol Chem.263(16):7500-7505.
Bischoff, R. et al., (1994). “Syntheissi Characterization of Photoactivation Peptide Agonists of the Human Thrombin Receptor,”FEBS Lett.349(2):301-306.
Bowie J. U. et al. (1990). “Deciphering the message in protein sequences: tolerance to amino acid substitutions,”Science247:1306-1310.
Campbell, A. M. (1986). “General Properties and Applications of Monoclonal Antibodies,” Chapter 1 inMonoclonal Antibody Technology, R.H. Burdon and P.H. van Knippenberg, eds. Elsievers Science Publishers, vol. 13, pp. 1-32.
Carney, D. H. et al. (1980). “Visualization of Thrombin Receptors on Mouse Embryo Fibroblasts Using Fluorescein-Amine Conjugated Human α-Thrombin,”J. Supranol. Struct.13(4):467-178.
Coller, B. S. et al. (1993). Substituting Isoserine for Serine in the Thrombin Receptor Activiation Peptide SFLLRN Confers Resistance to Aminopeptidase M-Induced Cleavage and Inactivation.The Journal of Biological Chemistry268(28):20741-20743.
Degen, S.J. and E.W. Davie. (1987). “Nucleotide Sequence of the Gene for Human Prothrombin,”Biochemistry26(19):6165-6177.
Gourdou, I. et al. (1990) “Neurotoxicity in Mice of Visna Virus HIV-1 Tat Proteins Cystein-rich Sequences,”C.R. Acad. Sci.Paris311(3):149-155.
Harris, W.J. and S. Emery. (1993). “Therapeutic Antibodies-The Coming of Age,”TIBTECH11:42-44.
Ishii, K. et al. (1993). “Kinetics of Thrombin Receptor Cleavage on Intact Cells,”J. Biol. Chem.268(13):9780-9786.
Layton, J.E. et al. (1989). “Epitope Mapping of Human Granulocyte-Macrophage Colony Stimulating Factor (hGM-CSF),”in HematopoiesisS.C. Clark and D.W. Golde. eds. Wiley-Liss, pp. 11-21.
Mascotti D. P. and T.M. Lohman. (1990). “Thermodynamic Extent of Counterion Relase Upon Binding Oligolysines to Single-Stranded Nucleic Acids,”Proc. Natl. Acad. Sci. U.S.A.87(8):3142-3146.
Power, S. D. et al. (1989). “The Engineering of Structural and Catalytic Properties of Proteins,” Chapter 6b,in BiotechnologyH.J. Rehm and G. Reen, eds., vol. 7b, VCH, pp. 262-276.
Waldmann, T. A. (1991). “Monoclonal Antibodies in Diagnosis and Therapy,”Science.
Coughlin Shaun R.
Scarborough Robert M.
Morrison & Foerster / LLP
The Regents of the University of California
Ulm John D.
LandOfFree
Recombinant thrombin receptor and related pharmaceuticals does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant thrombin receptor and related pharmaceuticals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant thrombin receptor and related pharmaceuticals will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3688651